Literature DB >> 34775012

Any Postoperative Surveillance Improves Survival after Endovascular Repair of Ruptured Abdominal Aortic Aneurysms.

Amanda R Phillips1, Elizabeth A Andraska2, Katherine M Reitz2, Lucine Gabriel3, Karim M Salem4, Natalie D Sridharan4, Edith Tzeng4, Nathan L Liang4.   

Abstract

BACKGROUND: Endovascular aortic repair (EVAR) has advanced the care of patients with ruptured abdominal aortic aneurysms (rAAA) with improved early postoperative morbidity and mortality. However, this comes at the cost of a rigorous postoperative surveillance schedule to monitor for further aneurysmal degeneration. Adherence to surveillance recommendations is known to be poor in the elective setting, but has yet to be studied in the ruptured population. The aim of this study is to investigate predictors of incomplete surveillance after EVAR for rAAA (rEVAR) and examine how adherence impacts outcomes.
METHODS: This was a retrospective case control study of patients undergoing rEVAR at a multiple hospital single healthcare center (2003-2020). Patients were excluded if they underwent open conversion during their index hospitalization or died within 60 days of surgery. Follow-up was broadly categorized as complete surveillance (60-day postoperative visit and annually thereafter) or incomplete surveillance, comprising both patients with less than recommended surveillance (minimal surveillance) and completely lost to follow-up (LTF). Any follow-up was defined as patients with complete or minimal surveillance. We investigated predictors of complete versus incomplete surveillance by multivariate logistic regression. Secondary outcomes included overall survival and cumulative incidence of reintervention controlling for the competing risk of mortality, generating hazard ratios (HR) and subdistribution hazard ratios (SHR).
RESULTS: One-hundred and sixty patients (mean age 74 ± 10.1 years, 81.2% male) out of 673 total rAAA met study inclusion criteria. Complete surveillance was seen in 41.3% of our cohort, with the remainder with minimal surveillance (29.4%) or LTF (29.4%). Incomplete surveillance was associated with male sex (odds ratio [OR] 2.56; 95% CI 1.02-6.43), lack of a primary care provider (PCP; OR 0.20; 95% CI 0.04-0.99), and longer driving distance from home to treating hospital (OR 2.37; 95% CI 1.08-5.20). Survival was not different between complete and incomplete surveillance groups, however any follow-up conferred improved survival over LTF (HR 0.57; 95% CI 0.331-0.997; P = 0.049). Reintervention was associated with incomplete surveillance (SHR 0.29; 95% CI 0.11-0.75), and discharge to a facility (SHR 0.25; 95% CI 0.067-0.94).
CONCLUSIONS: Incomplete surveillance was observed in over 50% of patients who underwent rEVAR and was associated with male sex, lack of PCP, and longer driving distance. Any follow-up conferred a survival benefit, yet incomplete surveillance was associated with a lower risk of reintervention. Targeted strategies to prevent LTF, and less stringent, personalized follow-up plans that may confer similar survival benefit with better patient adherence should be investigated.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2021        PMID: 34775012      PMCID: PMC8897248          DOI: 10.1016/j.avsg.2021.09.047

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  29 in total

1.  Factors Predicting Noncompliance with Follow-up after Endovascular Aneurysm Repair.

Authors:  Timothy P Shiraev; Elif Durur; David A Robinson
Journal:  Ann Vasc Surg       Date:  2018-05-21       Impact factor: 1.466

2.  Age, gender, and the underutilization of mental health services: the influence of help-seeking attitudes.

Authors:  C S Mackenzie; W L Gekoski; V J Knox
Journal:  Aging Ment Health       Date:  2006-11       Impact factor: 3.658

3.  Loss to follow-up after laparoscopic gastric bypass surgery - a post hoc analysis of a randomized clinical trial.

Authors:  Jonna Kedestig; Erik Stenberg
Journal:  Surg Obes Relat Dis       Date:  2019-03-20       Impact factor: 4.734

4.  Adherence to postoperative surveillance guidelines after endovascular aortic aneurysm repair among Medicare beneficiaries.

Authors:  Trit Garg; Laurence C Baker; Matthew W Mell
Journal:  J Vasc Surg       Date:  2014-07-31       Impact factor: 4.268

5.  Expanding use of emergency endovascular repair for ruptured abdominal aortic aneurysms: disparities in outcomes from a nationwide perspective.

Authors:  Kelly Lesperance; Charles Andersen; Niten Singh; Benjamin Starnes; Matthew J Martin
Journal:  J Vasc Surg       Date:  2008-04-03       Impact factor: 4.268

6.  "Lost to Follow-up" Among Adult Cancer Survivors.

Authors:  Amitoj Gill; Rohit Gosain; Shruti Bhandari; Rahul Gosain; Gurkirat Gill; Joseph Abraham; Kenneth Miller
Journal:  Am J Clin Oncol       Date:  2018-10       Impact factor: 2.339

7.  Endovascular or open repair strategy for ruptured abdominal aortic aneurysm: 30 day outcomes from IMPROVE randomised trial.

Authors:  Janet T Powell; Michael J Sweeting; Matthew M Thompson; Ray Ashleigh; Rachel Bell; Manuel Gomes; Roger M Greenhalgh; Richard Grieve; Francine Heatley; Robert J Hinchliffe; Simon G Thompson; Pinar Ulug
Journal:  BMJ       Date:  2014-01-13

Review 8.  Prevalence and risk factors of type II endoleaks after endovascular aneurysm repair: A meta-analysis.

Authors:  Qiang Guo; Xiaojiong Du; Jichun Zhao; Yukui Ma; Bin Huang; Ding Yuan; Yi Yang; Guojun Zeng; Fei Xiong
Journal:  PLoS One       Date:  2017-02-09       Impact factor: 3.240

9.  Effect of Imaging Surveillance After Endovascular Aneurysm Repair on Reinterventions and Mortality: A Systematic Review and Meta-analysis.

Authors:  Sylvana M L de Mik; Anna C M Geraedts; Dirk T Ubbink; Ron Balm
Journal:  J Endovasc Ther       Date:  2019-05-29       Impact factor: 3.487

10.  Barriers to Postpartum Follow-Up and Glucose Tolerance Testing in Women with Gestational Diabetes Mellitus.

Authors:  Ashley N Battarbee; Lynn M Yee
Journal:  Am J Perinatol       Date:  2017-10-11       Impact factor: 1.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.